Overview
Balance Sheet
Cash Flow
Growth Analysis
2024
2023
2022
2020
2019
Profitability Metrics
Gross Margin
79.70%
Operating Margin
76.76%
Net Margin
97.06%
Efficiency Metrics
Revenue per Expense Ratio
34.06
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
156.92%
Income Tax Rate
0.00%
EPS
0.4900000000
Balance Sheet Analysis
Current Ratio
-259,211.0
Cash Ratio
7,588,938.0
Working Capital
$720.02K
Debt to Equity
0.58
Debt to Assets
36.29%
Equity Ratio
62.60%
Cash Flow Analysis
Operating Cash Flow Ratio
143.64%
Free Cash Flow Ratio
143.64%
CapEx to Revenue
0.00%
Dividends Paid
$16.89M
Stock Buybacks
$3.92M
Total Shareholder Returns
$20.81M
Cash Position Change
106.27%
Key Takeaways (2024 FY)
Maintained positive net income growth despite revenue changes
Detailed Growth Metrics
Core Performance
Revenue
1,300.96%
Net Income
1,042.75%
EPS
1,058.90%
Operating Income
845.58%
Operational Efficiency
R&D Expenses
-100.00%
SG&A Expenses
100.23%
Operating Cash Flow
-56.41%
Free Cash Flow
-56.41%
Balance Sheet Health
Assets
-0.60%
Debt
341,993.65%
Book Value per Share
0.25%
Inventory
0.00%
Shareholder Returns
Dividends per Share
-4.27%
Shares Outstanding
-1.05%
Long Term Trends
3Y Revenue/Share
-43.43%
5Y Revenue/Share
-57.71%
3Y Dividend/Share
-26.88%
5Y Dividend/Share
-13.62%